Clinical Trial

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation, who received prior systemic anti-tumor treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-05; most recent amendment 2026-01-29.
Status change: Completed → Active, Not Recruiting 2026-01-29
Status change: Recruiting → Completed 2025-12-18
Status change: Not Yet Recruiting → Recruiting 2022-08-30
Trial Details
NCT Number NCT05043922
Lead Sponsor Haihe Biopharma Co., Ltd.
Conditions Ovarian Cancer, Recurrent Cancer
Enrollment 93 participants
Start Date 2021-10-11
Primary Completion 2024-07-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-30